BR112015020771A2 - composição farmacêutica de liberação temporizada - Google Patents
composição farmacêutica de liberação temporizadaInfo
- Publication number
- BR112015020771A2 BR112015020771A2 BR112015020771A BR112015020771A BR112015020771A2 BR 112015020771 A2 BR112015020771 A2 BR 112015020771A2 BR 112015020771 A BR112015020771 A BR 112015020771A BR 112015020771 A BR112015020771 A BR 112015020771A BR 112015020771 A2 BR112015020771 A2 BR 112015020771A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- release pharmaceutical
- timed release
- donepezil
- time
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
resumo composição farmacêutica de liberação temporizada a presente invenção refere-se a uma composição farmacêutica de liberação temporizada que compreende donepezila, em que a auc(14 a 22) de dose única da dita composição administrada de manhã é cerca de 5% a cerca de 30% menor que a auc(2 a 10) de dose única de uma composição de liberação imediata de donepezila administrada à noite, em que ambas as composições têm uma dose equivalente de donepezila. 1/1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN991KO2012 | 2013-02-28 | ||
PCT/IB2014/059302 WO2014132218A1 (en) | 2013-02-28 | 2014-02-27 | Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015020771A2 true BR112015020771A2 (pt) | 2017-07-18 |
Family
ID=50288205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015020771A BR112015020771A2 (pt) | 2013-02-28 | 2014-02-27 | composição farmacêutica de liberação temporizada |
Country Status (11)
Country | Link |
---|---|
US (1) | US20160015698A1 (pt) |
EP (1) | EP2961393B1 (pt) |
JP (1) | JP6429808B2 (pt) |
KR (1) | KR102241113B1 (pt) |
CN (1) | CN105163723A (pt) |
BR (1) | BR112015020771A2 (pt) |
ES (1) | ES2842208T3 (pt) |
MX (1) | MX2015011099A (pt) |
RU (1) | RU2015140567A (pt) |
WO (1) | WO2014132218A1 (pt) |
ZA (1) | ZA201506665B (pt) |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000030446A1 (en) * | 1998-11-23 | 2000-06-02 | Bonnie Davis | Dosage formulations for acetylcholinesterase inhibitors |
IL157634A0 (en) * | 2001-03-13 | 2004-03-28 | Penwest Pharmaceuticals Co | Chronotherapeutic dosage forms containing glucocorticosteroid |
US20070196481A1 (en) * | 2002-07-25 | 2007-08-23 | Amidon Gregory E | Sustained-release tablet composition |
US20050232990A1 (en) | 2003-12-31 | 2005-10-20 | Garth Boehm | Donepezil formulations |
CN101090737B (zh) * | 2004-12-27 | 2010-09-08 | 卫材R&D管理有限公司 | 稳定抗痴呆药物的方法 |
US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
CA2592605C (en) | 2004-12-27 | 2010-12-07 | Eisai R&D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
US20060159753A1 (en) | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Matrix type sustained-release preparation containing basic drug or salt thereof |
US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
US20060280789A1 (en) | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
AU2005325930B2 (en) * | 2005-01-27 | 2012-01-19 | Alembic Limited | Extended release formulation of Levetiracetam |
JP5666087B2 (ja) * | 2005-04-06 | 2015-02-12 | アダマス・ファーマシューティカルズ・インコーポレーテッド | Cns関連疾患の治療のための方法及び組成物 |
US20130059003A1 (en) | 2009-12-04 | 2013-03-07 | Dr. Reddy's Laboratories, Inc. | Sustained release donepezil formulations |
US20110218216A1 (en) | 2010-01-29 | 2011-09-08 | Kumaravel Vivek | Extended release pharmaceutical composition of donepezil |
EP2366378A1 (en) | 2010-03-01 | 2011-09-21 | Dexcel Pharma Technologies Ltd. | Sustained-release donepezil formulations |
GB201003734D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Delayed prolonged drug delivery |
CN102309465B (zh) * | 2010-06-30 | 2015-04-22 | 天津药物研究院 | 含盐酸多奈哌齐活性成分的缓释片及其制备方法和用途 |
WO2012035409A1 (en) * | 2010-09-14 | 2012-03-22 | Rubicon Research Private Limited | Sustained release compositions of anti-alzheimer's agents |
-
2014
- 2014-02-27 US US14/771,241 patent/US20160015698A1/en not_active Abandoned
- 2014-02-27 BR BR112015020771A patent/BR112015020771A2/pt not_active Application Discontinuation
- 2014-02-27 EP EP14710647.0A patent/EP2961393B1/en active Active
- 2014-02-27 ES ES14710647T patent/ES2842208T3/es active Active
- 2014-02-27 WO PCT/IB2014/059302 patent/WO2014132218A1/en active Application Filing
- 2014-02-27 MX MX2015011099A patent/MX2015011099A/es unknown
- 2014-02-27 RU RU2015140567A patent/RU2015140567A/ru not_active Application Discontinuation
- 2014-02-27 JP JP2015559595A patent/JP6429808B2/ja not_active Expired - Fee Related
- 2014-02-27 KR KR1020157026728A patent/KR102241113B1/ko active IP Right Grant
- 2014-02-27 CN CN201480024046.5A patent/CN105163723A/zh active Pending
-
2015
- 2015-09-09 ZA ZA2015/06665A patent/ZA201506665B/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2015140567A (ru) | 2017-03-31 |
JP2016513133A (ja) | 2016-05-12 |
JP6429808B2 (ja) | 2018-11-28 |
MX2015011099A (es) | 2016-04-06 |
WO2014132218A1 (en) | 2014-09-04 |
US20160015698A1 (en) | 2016-01-21 |
ZA201506665B (en) | 2017-02-22 |
CN105163723A (zh) | 2015-12-16 |
EP2961393A1 (en) | 2016-01-06 |
KR20150123302A (ko) | 2015-11-03 |
EP2961393B1 (en) | 2020-10-28 |
ES2842208T3 (es) | 2021-07-13 |
KR102241113B1 (ko) | 2021-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201690102A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
BR112017022604A2 (pt) | composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação | |
BR112014009391A2 (pt) | dosagem faseada de clopidogrel | |
BR112013031268A2 (pt) | "polipeptídeos análogos de pramlintida, uso dos mesmos, composição farmacêutica compreendendo os referidos polipeptídeos e método de preparação da referida composição". | |
MX2015008628A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
BR112015022545A2 (pt) | compostos de pirazolo e os usos disso | |
BR112014018027A8 (pt) | Composto, composição farmacêutica e usos dos mesmos e métodos para aumentar a inclusão de éxon 7 de ame2 em rnam que é transcrito a partir do gene ame2 e para aumentar a quantidade de proteína smn | |
BR112017023764A2 (pt) | derivados de ciclohexano substituído por amido | |
IN2014DN06501A (pt) | ||
CU20140081A7 (es) | Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
BR112015011430A2 (pt) | composição para liberação imediata e prolongada | |
BR112014010290B8 (pt) | Composição farmacêutica na forma de dispersão sólida de ativos específicos em polímeros específicos e uso da composição farmacêutica | |
BR112015022972A2 (pt) | composição farmacêutica de cloridrato de s-cetamina | |
DOP2015000005A (es) | Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
BR112016001446A8 (pt) | composições terapêuticas, produto de combinação, uso in vitro de flecainida e flecainida | |
DOP2014000059A (es) | Derivados de estra1,3,5(10),16tetraen3carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
BR112015018504A2 (pt) | moduladores de flap | |
BR112018000739A2 (pt) | composições farmacêuticas contendo celecoxib e tramadol | |
MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
GT201300322A (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib | |
GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
MX2016000294A (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
BR112017001000A2 (pt) | composições de açúcar para preparação de comprimidos por compressão direta | |
UY33723A (es) | ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?. | |
BR112016009572A2 (pt) | Análogo de relaxina humana, composição farmacêutica do mesmo e aplicação farmacêutica do mesmo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |